Marie Schongar
Nurse Practitioner · Albany, NYNPI 1891898987
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 86.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $13,742 and has fallen 85.3% since, to $2,019 in 2025. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $148.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Dexcom, Inc.$631
- Sanofi-aventis U.S. LLC$516
- Amgen$446
- Insulet Corporation$295
- Lilly USA, LLC$275
- plus $1K from 9 others
What the payments were for
- Consulting fees$1,3886%
- Speaking & faculty fees$10,35042%
- Travel & lodging$5,38722%
- Food & beverage$7,73231%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 123 | $21,385 |
| Dexcom, Inc. | 9 | $631 |
| Sanofi-aventis U.S. LLC | 5 | $516 |
| Amgen | 4 | $446 |
| Insulet Corporation | 2 | $295 |
| Lilly USA, LLC | 6 | $275 |
| Novo Nordisk | 3 | $257 |
| Abbott | 3 | $214 |
| Sequel Med Tech, LLC | 2 | $204 |
| Intuity Medical Inc | 4 | $191 |
| AstraZeneca | 1 | $123 |
| Bayer | 1 | $98 |
| Embecta Corp. | 1 | $91 |
| BETA Bionics, Inc. | 2 | $84 |
| Bigfoot Biomedical Inc | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 630G$9,673
- INPEN SMART INSULIN DELIVERY SYSTEM$4,233
- MINIMED 780G$2,935
- Minimed 770G System$869
- InPen$503
- DEXCOM G6 TRANSMITTER$461
- EVENITY$382
- TZIELD$326
- Omnipod$295
- MINIMED 770G$265
- TWIIST$150
- Prolia$136
- FARXIGA$123
- Ozempic$120
How this compares
$24,873 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $137,220 |
| TrulicityDulaglutide | 65 | $88,626 |
| JardianceEmpagliflozin | 72 | $75,472 |
| MounjaroTirzepatide | 61 | $70,256 |
| FiaspInsulin Aspart (Niacinamide) | 45 | $54,960 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $32,567 |
| RybelsusSemaglutide | 18 | $25,690 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $21,811 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $20,772 |
| HumalogInsulin Lispro | 39 | $20,459 |
| FarxigaDapagliflozin Propanediol | 12 | $15,884 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $15,720 |
| NovologInsulin Aspart | 70 | $15,369 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $14,878 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $14,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $257 | $233,238254 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $275 | $180,385176 claims |
| AstraZenecaFarxiga | $123 | $15,88412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Albany
- Valerie StanleyAlbany$55K
- Elizabeth NardacciAlbany$18K
- Stephen JonesAlbany$18K
- Elvira FawAlbany$16K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.